A recent study compared the cutaneous toxic effects of BRAF inhibitor monotherapy and combination dabrafenib with MEK inhibitor trametinib dimethyl sulfoxide (CombiDT therapy) in a large cohort of patients. Results confirm that prevalence of cutaneous toxic effects differs among vemurafenib, dabrafenib, and CombiDT therapies. Cutaneous squamous cell carcinoma was the most concerning cutaneous toxic effect related to BRAF inhibitor monotherapy that did not appear with CombiDT therapy.
- Retrospective cohort study of 185 Australian patients with unresectable stages IIIC and IV melanoma
- 119 patients received dabrafenib; 36, vemurafenib; and 30, Combi...